Table 1. Demographic and clinical characteristics of 16 patients with glioblastomas who received KMT.
Astro, astrocytoma; BCNU, carmustine wafers; BVZ, bevacizumab; Dx, diagnosis; FU, follow-up; GBM, glioblastoma; GT, GammaTile; IMRT, intensity-modulated radiation therapy; KMT, ketogenic metabolic therapy; KPS, Karnofsky Performance Status; LITT, laser interstitial thermal therapy; NA, not available; oligo, oligodendroglioma; PFS, progression-free survival; Pt., patient; RANO, Response Assessment in Neuro-oncology; SRS, stereotactic radiosurgery; TMZ, temozolomide; TTF, tumor-treating fields; WHO, World Health Organization.
| Pt. | Age at Dx, yr/Sex | Pathologic WHO Grade (Grade at Original Dx) | Pathologic Subtype | IDH1 Mutant | MGMT | Duration of KMT, mo. | Ketone Level, mM | Intermittent Fasting | RANO Response During KMT | PFS With KMT, mo. | Radiographic Progression During KMT | Radiographic Progression After KMT Cessation | Adjuvant Treatment | Last FU KPS |
| 1 | 36/M | III | Oligo | + | - | 36 | 1.5-4.5 | + | Partial | 18 | - | Yes | TMZ, BVZ, GT, BCNU, LITT, SRS, TTF | 0 |
| 2 | 42/F | IV (III) | Oligo | + | + | 12 | 1.0 | + | Complete | 6 | Yes | - | TMZ, IMRT, BVZ, GT, BCNU, TTF | 0 |
| 3 | 59/F | III | Astro | + | + | 36 | 0.5-1.8 | - | Complete | 34 | No | - | TMZ, IMRT | 90 |
| 4 | 25/M | IV (II) | Oligo-astro | + | + | 12 | NA | - | Partial | 8 | Yes | - | TMZ, IMRT, GT, BCNU, LITT, TTF | 0 |
| 5 | 58/M | IV | GBM | NA | + | 3 | 1.0 | - | Partial | 3 | No | - | TMZ, IMRT, LITT | 90 |
| 6 | 50/M | III | Astro | + | + | 12 | NA | - | Partial | 12 | No | - | TMZ, IMRT, LITT, TTF | 90 |
| 7 | 56/M | IV (II) | Oligo with sarcomatous features | + | NA | 7 | 0.5-1.0 | + | Partial | 7 | - | Yes | TMZ, IMRT, BVZ, BCNU, LITT, SRS, TTF | 20 |
| 8 | 75/M | IV | GBM | - | NA | 6 | 1.5 | NA | Partial | 6 | No | - | TMZ, IMRT, TTF | 90 |
| 9 | 53/M | IV | Gliosarcoma | - | NA | 12 | NA | + | Partial | 12 | - | Yes | TMZ, IMRT | 0 |
| 10 | 35/F | IV | GBM | + | + | 20 | 0.5-2.0 | + | Partial | 20 | - | Yes | TMZ, IMRT, BVZ, GT, BCNU, SRS, TTF | 80 |
| 11 | 44/M | II | Oligo | + | + | 48 | 0.2-1.0 | - | Complete | 48 | No | - | 90 | |
| 12 | 48/M | III | Oligo | + | NA | 12 | 0.2-2.5 | - | Complete | 12 | No | - | TMZ, IMRT, GT, LITT, SRS | 90 |
| 13 | 27/M | III | Astro | + | - | 24 | 4.0-5.0 | + | Partial | 24 | No | - | TMZ, IMRT, TTF | 100 |
| 14 | 53/M | III | Astro | - | - | 12 | 1.0-3.5 | + | Progression | 0 | Yes | - | TMZ, IMRT, BVZ, GT, LITT, TTF | 80 |
| 15 | 54/F | IV | GBM | + | + | 22 | 0.3-1.0 | - | Partial | 22 | No | - | TMZ, IMRT, BVZ, BCNU, LITT, TTF | 70 |
| 16 | 57/F | III (II) | Oligo | + | NA | 3 | NA | - | Partial | 3 | No | - | TMZ, IMRT, LITT, SRS | 90 |